PD1 EXPRESSION RELAPSE NHL AUTOLOGOUS HCT
Reading File
Searching PubMed
PD-1 expression relapse non-Hodgkin lymphoma autologous hematopoietic cell transplantation
Finding Sources
Searching PubMed
PD-1 checkpoint NHL relapse autologous stem cell transplant
Finding Sources
Finding Sources
Searching PubMed
PD-1 expression tumor microenvironment diffuse large B cell lymphoma prognosis
Reading File
Reading Article
PMID: 38183180
Reading Article
PMID: 32394185
Searching PubMed
PD-1 positive T cells NHL relapse post autologous transplant nivolumab pembrolizumab
Reading File
Finding Sources
Searching PubMed
checkpoint inhibitor maintenance relapsed lymphoma post autologous transplant
Reading Article
PMID: 38708156
Reading Article
PMID: 37760478
Searching the Web
PD-1 expression predicts relapse after autologous HCT NHL DLBCL tumor microenvironment
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC10171206
I now have sufficient data to compose a thorough answer. Here is the full synthesis:
PD-1 Expression, Relapse in NHL, and Autologous HCT
1. PD-1/PD-L1 Biology in NHL
PD-1 (programmed cell death protein-1, CD279) is an inhibitory co-receptor expressed on activated and exhausted T cells. When it binds its ligands (PD-L1/CD274 or PD-L2/CD273), it activates a phosphatase that suppresses T-cell receptor signaling, effectively putting anti-tumor T cells into an "exhausted" or tolerized state. Tumor cells and stromal cells that upregulate PD-L1 exploit this mechanism to evade immune destruction (Robbins Pathologic Basis of Disease, "Mechanisms of Immune Evasion by Cancers").
In NHL, PD-1 is expressed in two distinct contexts:
- On tumor-infiltrating lymphocytes (TILs) - PD-1+ T cells in the tumor microenvironment (TME)
- On the neoplastic cells themselves - in specific NHL subtypes (notably angioimmunoblastic T-cell lymphoma, follicular T-helper cell lymphomas, and some DLBCL)
2. PD-1/PD-L1 and Prognosis in NHL Subtypes
Diffuse Large B-Cell Lymphoma (DLBCL) - the most relevant histology for auto-HCT
The prognostic significance of PD-1 expression is paradoxical and context-dependent in DLBCL:
PD-1+ TILs (tumor-infiltrating lymphocytes):
A 2024 meta-analysis of 25 studies (4,495 DLBCL patients) found that high density of PD-1+ TILs is associated with BETTER overall survival in DLBCL (Zhao et al., PMID 38183180). This likely reflects an active anti-tumor immune response - the PD-1+ cells represent reactive immune effectors attempting to attack tumor. The same meta-analysis showed that high PD-L1+ tumor cells (unlike PD-1+ TILs) predict worse OS.
A separate IHC study of 52 nodal DLBCL cases confirmed: patients with PD-1 expression <5 positive cells/HPF had significantly worse overall survival, suggesting that loss of PD-1+ TIL infiltration is a poor prognostic marker (PMID 38708156, Atmış et al., 2024).
PD-L1 on tumor or microenvironmental cells:
- In DLBCL, chromosome 9p24.1 amplification (which drives PD-L1/PD-L2 overexpression) is seen in only ~5-10% of cases (compared to ~90% in classical Hodgkin lymphoma)
- Some DLBCL subtypes with high PD-L1 include EBV+ DLBCL, primary mediastinal B-cell lymphoma (PMBCL), and primary CNS DLBCL (PCNS-DLBCL)
- Evidence on PD-L1's prognostic value in DLBCL is conflicting - some studies show better PFS with high PD-L1 (possible marker of an immune-active TME), others show worse OS (Xie et al., PMID 32394185)
Key distinction by cell of origin (COO):
| Subtype | PD-L1/9p24.1 frequency | PD-1 blockade efficacy |
|---|---|---|
| Classical Hodgkin Lymphoma | ~90% | High (~70% ORR with nivolumab/pembrolizumab) |
| PMBCL | ~65% | Intermediate |
| GCB-DLBCL | ~5-10% | Low in unselected patients |
| non-GCB/ABC-DLBCL | Variable | Marginally better, still low |
| EBV+ DLBCL | High | Promising |
| PCNS-DLBCL | Variable | Some responses, especially high TMB + PD-1+ TILs |
3. Auto-HCT in Relapsed/Refractory NHL
Standard role
Autologous HCT (auto-HCT, ASCT) remains a cornerstone treatment for chemosensitive relapsed/refractory NHL - most importantly for DLBCL. The PARMA trial established auto-HCT as standard over salvage chemotherapy alone for chemosensitive relapse. Cecil Medicine notes auto-HCT as "the standard of care for patients with primary refractory or chemotherapy-sensitive relapsed NHL of specific histologies, including DLBCL" (Goldman-Cecil Medicine, block 21).
Disease-free survival rates with auto-HCT:
- DLBCL: ~40-50% long-term in chemosensitive relapse
- Follicular NHL: up to 60% disease-free survival
- Mantle cell lymphoma: improved PFS especially with post-transplant maintenance rituximab
Post-auto-HCT relapse: a critical unmet need
Up to 50% of DLBCL patients who undergo auto-HCT will still relapse or have refractory disease. Prognosis after post-ASCT relapse is poor, with median OS historically <6 months in the pre-CAR-T era. The CORAL study follow-up demonstrated dismal outcomes for DLBCL relapsing after ASCT.
4. PD-1 Checkpoint Inhibitors: Before, During, and After Auto-HCT in NHL
Classical Hodgkin Lymphoma (cHL) - Highest evidence base
PD-1 inhibitors are FDA-approved and the most impactful in cHL due to near-universal 9p24.1 amplification. Three strategic timepoints exist:
A) Pre-transplant (salvage before ASCT)
- Nivolumab and pembrolizumab achieve ORR of ~65-70% in R/R cHL
- PD-1 blockade before ASCT bridges patients to transplant and improves the depth of remission (CMR rate), which is the strongest predictor of post-transplant outcomes
- An ASH 2023 multicenter cohort confirmed: PD-1 blockade before ASCT improves outcomes in R/R cHL
B) Post-transplant maintenance
- Pembrolizumab and nivolumab as post-ASCT consolidation/maintenance are under active study
- KEYNOTE-667 evaluated pembrolizumab maintenance after ASCT in high-risk cHL; CHECKMATE 731 evaluated nivolumab
- The AETHERA trial established brentuximab vedotin (BV) post-ASCT maintenance; BV + PD-1 inhibitor combinations are being explored
C) Treatment of relapse after ASCT
- PD-1 inhibitors are first-line options for cHL relapsing after ASCT
- Nivolumab: ORR ~69%, CR ~16% in post-ASCT R/R cHL (CheckMate 205)
- Pembrolizumab: ORR ~69% (KEYNOTE-087)
(Randall & Spinner, Cancers, 2023, PMID 37760478; Zhang & Collins, PMID 35696020)
NHL subtypes (non-cHL) post-auto-HCT
For DLBCL relapsing after ASCT:
- CAR-T cell therapy (axicabtagene ciloleucel, lisocabtagene maraleucel) is now standard of care post-ASCT relapse
- PD-1 inhibitors (nivolumab, pembrolizumab) have low ORR (~5-10%) in unselected DLBCL, reflecting infrequent 9p24.1 amplification
- Exceptions: EBV+ DLBCL, PCNS-DLBCL, and DLBCL with high TMB + PD-1+ TIL infiltration may respond - as demonstrated by a PCNS-DLBCL case maintaining 3-year CR on nivolumab after multiple ASCT failures (high TMB + PD-1+ TILs on IHC)
- PD-1 inhibitor maintenance after CAR-T in relapsed/refractory B-cell NHL has shown efficacy in improving outcomes (Xin et al., PMID 38564164, 2024)
5. Biological Rationale: Why PD-1 Checkpoint Status Matters for Transplant Outcomes
Auto-HCT delivers high-dose chemotherapy that clears bulk tumor. However, residual PD-1-exhausted T cells in the graft and a reconstituting immune system post-transplant that is enriched with PD-1+ exhausted effectors may contribute to relapse by failing to eliminate minimal residual disease. Key mechanisms:
- Graft composition: PD-1 expression on the collected stem cell product's T-cell compartment may affect post-transplant immune reconstitution and graft-versus-tumor activity
- Immune reconstitution: Post-ASCT T-cell recovery is dominated by PD-1+ exhausted CD8+ cells for months, impairing tumor surveillance
- Tumor immune escape: Residual tumor cells upregulate PD-L1 in the post-transplant immunosuppressed milieu
- Microenvironment reset: Conditioning eliminates TILs; post-transplant immune reinfiltration determines whether immune control is re-established
6. Practical Clinical Decision Points
| Clinical scenario | Preferred approach |
|---|---|
| R/R cHL, chemosensitive, ASCT candidate | PD-1 inhibitor ± BV salvage → ASCT → consider BV maintenance |
| R/R cHL, post-ASCT relapse | PD-1 inhibitor (nivolumab or pembrolizumab) first-line |
| R/R DLBCL, ASCT candidate | Standard salvage chemo (R-DHAP, R-ICE) → ASCT; PD-1 inhibitors not standard |
| R/R DLBCL, post-ASCT relapse | CAR-T cell therapy (if eligible); PD-1 inhibitors for selected subtypes (EBV+, high TMB, PCNS) |
| DLBCL with PD-1+ TIL-rich TME | May predict better chemo response; not a standard indication for PD-1 blockade |
Summary
- PD-1+ TILs in DLBCL TME are a favorable prognostic marker (better OS/PFS), while PD-L1 on tumor cells has conflicting prognostic significance
- Auto-HCT remains standard for chemosensitive relapsed NHL (especially DLBCL), with 40-60% long-term disease-free survival
- Post-ASCT relapse occurs in ~50% of DLBCL patients and historically carries poor prognosis; CAR-T has transformed management
- PD-1 blockade has its greatest impact in cHL (due to universal 9p24.1/PD-L1 amplification) - pre-ASCT salvage, post-ASCT maintenance, and post-ASCT relapse
- For non-cHL NHL, unselected use of PD-1 inhibitors post-ASCT has limited efficacy; response is restricted to PD-L1-high or EBV-driven subtypes
- Recent evidence (2024-2026) is exploring PD-1 inhibitor maintenance post-CAR-T and combining checkpoint blockade with bispecifics for broader NHL applicability
Key references:
- Zhao et al. (2024), meta-analysis of TME in DLBCL - PMID 38183180
- Xie et al. (2020), PD-1/PD-L1 in large-cell lymphomas - PMID 32394185
- Randall & Spinner (2023), R/R cHL management with immunotherapy - PMID 37760478
- Atmış et al. (2024), PD-1 TIL density and survival in DLBCL - PMID 38708156
- Goldman-Cecil Medicine, "Non-Hodgkin Lymphoma" and "Hematopoietic Cell Transplantation" chapters
USE OF PD1 INHIBITORS PRIOR TO AUTOLOGOUS BMT AND GVHD
Reading File
Searching PubMed
PD-1 inhibitor prior autologous stem cell transplantation toxicity outcomes
Searching PubMed
nivolumab pembrolizumab before autologous transplant graft failure engraftment
Finding Sources
Searching PubMed
checkpoint inhibitor Hodgkin lymphoma autologous transplant immune adverse events engraftment
Searching PubMed
PD-1 blockade before allogeneic transplant graft versus host disease hyperacute
Reading Article
PMID: 42075609
Reading Article
PMID: 40025210
Searching PubMed
immune checkpoint inhibitor prior allogeneic transplant GVHD hyperacute severe
Searching PubMed
nivolumab pembrolizumab salvage bridge autologous HCT Hodgkin lymphoma feasibility
Searching PubMed
PD-1 inhibitor prior allogeneic transplant graft versus host disease fatal
Searching PubMed
autologous engraftment syndrome PD-1 inflammation corticosteroid
Searching the Web
PD-1 inhibitor before autologous BMT GVHD engraftment syndrome irAE clinical guidelines 2024 2025
Reading Article
PMID: 37516808
Reading Article
PMID: 31140644
Reading Web Page
https://www.mdpi.com/1648-9144/62/4/738
I now have excellent, comprehensive data. Let me compose the full answer:
PD-1 Inhibitors Prior to Autologous BMT and GVHD
The Core Conceptual Point: Auto-BMT Does Not Cause Classical GVHD
True graft-versus-host disease (GVHD) requires allogeneic donor T cells recognizing host antigens as foreign. Since autologous BMT/HCT uses the patient's own hematopoietic stem cells, classical GVHD cannot occur - there is no genetically foreign donor. This is a fundamental distinction.
However, prior PD-1 inhibitor exposure introduces several distinct immune complications that mimic, overlap with, or replace classical GVHD as a clinical concern. There are also important considerations for patients who later proceed to allogeneic transplant after PD-1 exposure.
1. PD-1 Inhibitors as Salvage/Bridge to Auto-BMT: Efficacy
PD-1 inhibitors (nivolumab, pembrolizumab) are increasingly used as salvage therapy in relapsed/refractory classical Hodgkin lymphoma (cHL) prior to autologous HCT. The clinical rationale:
- ORR ~65-70% in R/R cHL with PD-1 inhibitors
- Patients who achieve CR or PR can then proceed to ASCT for consolidation
- PD-1 blockade may "chemosensitize" heavily pre-treated, chemorefractory cHL - as shown in a real-world Italian cohort of 45 patients where auto-SCT consolidation after CPI achieved 93.3% ORR (all CR), with median survivals not reached and no unexpected cumulative toxicities (Pellegrini et al., 2025, PMID 40025210)
- At a median interval of 41 days from last PD-1 inhibitor dose to ASCT, outcomes were excellent: 2-year PFS 73%, 2-year OS 82% in PD-1-exposed HL patients proceeding to ASCT (Ibrahim et al., cited in Tóthfalusi et al., 2026)
2. What Happens Instead of GVHD: Immune Complications Specific to PD-1-Exposed Auto-BMT Patients
A. Pre-Engraftment Syndrome (Pre-ES) - the most important new finding
A 2026 Hungarian single-center retrospective study of 64 HL patients undergoing ASCT (2018-2025) identified a striking association between prior PD-1 inhibitor exposure and pre-engraftment syndrome (pre-ES) - an early inflammatory complication occurring before neutrophil recovery (Tóthfalusi et al., Medicina, 2026, PMID 42075609):
| Finding | Data |
|---|---|
| Classical ES (Spitzer criteria, in window) | 0% |
| Maiolino-defined pre-ES (any severity) | 53.1% |
| Steroid-requiring severe pre-ES | 3 patients - ALL in PD-1-exposed group |
| Association with prior PD-1 exposure | p = 0.0007 |
| Biomarker: early CRP elevation | Significantly higher in PD-1-exposed patients |
Key points:
- All clinically significant (steroid-requiring) pre-ES cases occurred exclusively in PD-1-exposed patients
- The shorter the interval between last PD-1 dose and ASCT, the higher the apparent risk (trend, not statistically significant due to small numbers)
- Pre-ES closely mimics infection - this is clinically dangerous because it may delay recognition and treatment
- Management: once infection is excluded, prompt systemic corticosteroids are potentially life-saving
Mechanism: Residual immune activation from recent PD-1 blockade primes T cells in the graft to generate an exaggerated cytokine release during the engraftment-phase leukocyte surge.
B. Engraftment Syndrome (ES) - across reported case series
Multiple case series/reports document engraftment syndrome in PD-1-exposed patients at ASCT:
- Ibrahim et al. (2024): 11/11 HL patients who received pembrolizumab (n=7) or nivolumab (n=4) prior to ASCT developed ES, all requiring corticosteroids
- Choi et al. (2026): 3/3 patients (all PD-1-exposed) developed ES at median day +10
- Demirsoy et al. (2025): Case report of ES after ASCT in a nivolumab-treated patient
C. Cytokine Release Syndrome (CRS)
A documented case report (Sindel et al., Eur J Haematol, 2019, PMID 31140644) described:
- Patient received nivolumab for R/R Hodgkin lymphoma, then underwent stem cell mobilization and ASCT
- Post-transplant: frank cytokine storm with marked T-cell proliferation coincident with myeloid engraftment
- Complications: non-cardiogenic pulmonary edema + alveolar hemorrhage
- Refractory to corticosteroids but resolved with IV ascorbic acid
- The activated T cells mobilized during/after PD-1 blockade were retained in the graft, driving the cytokine storm upon engraftment
D. Immune-Related Adverse Events (irAEs) Persisting Through Transplant
PD-1 inhibitors have a half-life of ~27 days (nivolumab) to ~22 days (pembrolizumab), and their immune effects outlast clearance of drug by weeks to months. Active irAEs at the time of ASCT (pneumonitis, colitis, hepatitis, etc.) are a contraindication to proceeding.
| irAE concern | Clinical implication |
|---|---|
| Active irAE at ASCT | Delay transplant, treat irAE first |
| Resolved irAE with steroid taper | Proceed cautiously; risk of flare with conditioning |
| Conditioning immunosuppression | May suppress or unmask irAEs unpredictably |
3. A Critical Distinction: PD-1 Before Allogeneic (Not Auto) Transplant - Where GVHD IS a Concern
If a patient received PD-1 inhibitors and then proceeds to allogeneic HCT (not autologous), the GVHD risk is real and serious:
- Retrospective studies of allo-HCT after prior CPI exposure showed favorable survival but high rates of GVHD - including severe, steroid-refractory, and fatal cases (Alkhaldi et al., PMID 37516808, Bone Marrow Transplant, 2023)
- Mechanism: Residual PD-1 blockade augments alloreactive donor T cells - which normally require PD-1 signaling as a brake. Without that brake, donor T cells responding to host alloantigens cause hyperacute or severe GVHD
- Post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis appears to mitigate this risk most effectively compared to standard CNI + MTX prophylaxis
- The optimal washout period before allo-HCT remains undefined - most centers aim for ≥4-6 weeks minimum; longer washout may reduce but not eliminate risk
Key clinical rule: CPI use after allo-HCT (for post-transplant relapse) also carries serious GVHD risk - both GVHD precipitation and GVHD worsening have been reported, including fatal cases.
4. Autologous "GVHD-like" Phenomenon
The EBMT Handbook describes engraftment syndrome in the auto-HCT context also under the historical term "autologous GVHD" - this is not true GVHD but rather the clinical syndrome of fever, rash, diarrhea, and pulmonary infiltrates during engraftment driven by cytokine release, not allorecognition. In PD-1-exposed patients, this autologous GVHD-like state appears amplified.
5. Timing, Washout, and Clinical Recommendations
| Parameter | Current evidence / practice |
|---|---|
| Minimum PD-1 inhibitor to ASCT interval | No formal guideline; reported series used 30-146 days (median ~41 days) |
| Risk factor for severe pre-ES | Shorter interval between last PD-1 dose and ASCT |
| Monitoring post-ASCT | Daily CRP, close watch for fever/rash/pulmonary signs in first 2 weeks |
| Treatment threshold | Low - start corticosteroids early after excluding infection |
| Stem cell mobilization after PD-1 | Generally adequate; activated T cells co-mobilized with CD34+ cells |
| Active irAE | Must be resolved before proceeding to ASCT |
| PD-1 before allo-HCT | Additional GVHD risk - prefer PTCy prophylaxis; expert consensus recommended |
Summary
| Clinical scenario | GVHD risk | Main immune complication | Management |
|---|---|---|---|
| PD-1 inhibitor → autologous BMT | None (no classical GVHD possible) | Pre-engraftment syndrome, ES, CRS | Early CRP monitoring; prompt corticosteroids |
| PD-1 inhibitor → allogeneic BMT | High - severe/fatal GVHD reported | Hyperacute/severe GVHD | PTCy prophylaxis; ≥4-6 wk washout |
| PD-1 inhibitor after allo-HCT | High - GVHD precipitation | Acute GVHD exacerbation | Use with extreme caution; expert supervision |
Key references:
- Tóthfalusi et al. (2026) - pre-ES after ASCT in PD-1-exposed R/R HL - PMID 42075609
- Pellegrini et al. (2025) - outcomes of auto-SCT consolidation after CPI in cHL - PMID 40025210
- Alkhaldi et al. (2023) - CPI after allo-HCT, GVHD risk - PMID 37516808
- Sindel et al. (2019) - cytokine storm after ASCT in nivolumab-mobilized patient - PMID 31140644
This is a shared conversation. Sign in to Orris to start your own chat.